Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Investing.com - UBS lowered its price target on Align Technology (NASDAQ:ALGN) to $155 from $160 while maintaining a Neutral rating on Thursday. According to InvestingPro data, the stock currently trades at $130.67, with analysts’ targets ranging from $140 to $220.
The dental equipment maker’s stock has declined 38% year-to-date and is down 81% from its 2021 highs, now trading at historically low multiples following disappointing second-quarter results. InvestingPro analysis shows the company maintains a strong balance sheet with more cash than debt, while management has been actively buying back shares - two of several ProTips available to subscribers.
UBS cited multiple factors weighing on Align’s performance, including aligners losing category share versus traditional wires and brackets for the first time in years, perceived market share losses to competitors, and price declines signaling weakness in the Invisalign positioning and pricing model.
The firm noted that tepid consumer confidence and management’s diminished ability to forecast its business have created investor skepticism about the company’s ability to achieve its fourth-quarter sales growth targets, which require at least 3% year-over-year growth compared to negative growth in the first three quarters of 2025.
UBS believes investors have only modest conviction that Align Technology can meet consensus estimates for the third quarter and are skeptical the company can maintain its full-year guidance of flat to slightly higher year-over-year sales.
In other recent news, Align Technology has been in the spotlight with several significant developments. Mizuho has adjusted its price target for Align Technology to $170.00 from $210.00, while maintaining an Outperform rating, expecting third-quarter 2025 revenues of $985 million, slightly above the Street’s estimate of $976 million. Jefferies, however, downgraded Align Technology from Buy to Hold, reducing its price target to $140.00 from $215.00 due to concerns about market penetration and share loss, as revealed by their U.S. Dental Survey. Align Technology has also filed a complaint with the U.S. International Trade Commission against Angelalign Technology over alleged patent infringements, seeking to block the importation and sale of certain products in the U.S.
Piper Sandler has reiterated its Overweight rating and a $190.00 price target for Align Technology, highlighting the company’s ongoing patent litigation efforts across multiple regions, including the United States, Europe, and China. Stifel maintains a Buy rating with a $200.00 price target, noting Align Technology’s new pricing strategies aimed at boosting market share among teenagers and retaining providers. These developments reflect Align Technology’s active engagement in both market strategies and legal actions, as it navigates challenges and opportunities in the clear aligner industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.